Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,234 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali sold 1,234 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the completion of the transaction, the chief financial officer now owns 37,163 shares of the company’s stock, valued at approximately $933,162.93. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Asif Ali also recently made the following trade(s):

• On Friday, March 1st, Asif Ali sold 14,248 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $32.24, for a total transaction of $459,355.52.

Protagonist Therapeutics Stock Up 1.5 %

PTGX opened at $25.61 on Friday. The firm’s fifty day simple moving average is $28.52 and its 200 day simple moving average is $22.91. Protagonist Therapeutics, Inc. has a 12 month low of $13.72 and a 12 month high of $33.34.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.05 by $0.39. The business had revenue of $60.00 million for the quarter, compared to the consensus estimate of $60.00 million. On average, research analysts predict that Protagonist Therapeutics, Inc. will post 1.18 earnings per share for the current year.

Analysts Set New Price Targets

PTGX has been the topic of several research reports. JPMorgan Chase & Co. boosted their price objective on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Protagonist Therapeutics in a research report on Wednesday, February 28th. Finally, StockNews.com raised shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Institutional Investors Weigh In On Protagonist Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. lifted its position in Protagonist Therapeutics by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 34,895 shares of the company’s stock worth $1,010,000 after buying an additional 849 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in Protagonist Therapeutics by 236.8% during the 1st quarter. Los Angeles Capital Management LLC now owns 30,827 shares of the company’s stock worth $892,000 after buying an additional 21,673 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Protagonist Therapeutics by 10.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 515,220 shares of the company’s stock worth $11,814,000 after buying an additional 48,017 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Protagonist Therapeutics during the 4th quarter worth about $454,000. Finally, Virtus ETF Advisers LLC lifted its position in Protagonist Therapeutics by 29.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,457 shares of the company’s stock worth $102,000 after buying an additional 1,017 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.